Valuation: Ocugen, Inc.

Market Cap 251M 224M 207M 188M 352M 23.81B 357M 2.49B 984M 12.48B 941M 921M 39.35B P/E 2026 *
-2.86x
P/E 2027 * -2.74x
Enterprise Value 184M 164M 152M 138M 258M 17.49B 262M 1.83B 723M 9.17B 691M 677M 28.91B EV / Sales 2026 *
37.2x
EV / Sales 2027 * 45.6x
Free-Float
98.56%
Yield 2026 *
-
Yield 2027 * -
1 day-6.37%
1 week-5.20%
Current month-28.18%
1 month-26.03%
3 months-38.87%
6 months-55.44%
Current year-45.21%
1 week 0.73
Extreme 0.732
0.84
1 month 0.73
Extreme 0.732
1.12
Current year 0.73
Extreme 0.732
2.72
1 year 0.73
Extreme 0.732
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 26/09/2019
Director of Finance/CFO - 08/02/2026
Chief Operating Officer - 28/02/2026
Director TitleAgeSince
Chairman 62 26/09/2019
Director/Board Member 59 31/08/2013
Director/Board Member 59 31/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Sell

Chief Executive Officer

-525,991 0.1551%
09/09/26 Sell

Chief Executive Officer

-525,991 0.1551%
01/04/26 Exercice

Director

388,268 0.1184%
Change 5-day change 1-year change 3-year change Capi.($)
-6.37%-5.20%-54.06%+87.17% 251M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average -0.39%+1.65%+37.87%+135.52% 38.34B
Weighted average by Cap. +0.39%+2.73%+45.95%+142.80%

Financials

2026 *2027 *
Net sales 4.96M 4.42M 4.09M 3.71M 6.95M 471M 7.05M 49.18M 19.45M 247M 18.6M 18.21M 778M 5.5M 4.91M 4.54M 4.11M 7.71M 522M 7.82M 54.57M 21.58M 274M 20.64M 20.2M 863M
Net income -86.69M -77.34M -71.5M -64.82M -121M -8.23B -123M -860M -340M -4.31B -325M -318M -13.6B -94.65M -84.44M -78.07M -70.78M -133M -8.99B -135M -939M -371M -4.71B -355M -348M -14.85B
Net Debt -66.6M -59.41M -54.93M -49.8M -93.34M -6.32B -94.69M -661M -261M -3.31B -250M -245M -10.45B -
Projected Income Statement - Annual - Ocugen, Inc.
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
23/10/26 US$0.7397 -6.37% 8,585,242
22/10/26 US$0.7900 -3.08% 6,718,956
21/10/26 US$0.8151 +0.32% 4,321,941
20/10/26 US$0.8125 +3.20% 6,661,941
19/10/26 US$0.7873 +0.90% 4,471,406
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Ocugen, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7397USD
Average target price
12.17USD
Spread / Average Target
+1,544.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ocugen, Inc.
  1. Stock Market
  2. Stocks
  3. OCGN Stock